


Supplementary Figure S3



Supplementary Figure S3. PI3Ki/MEKi combination therapy drives tumor control in majority of Pb-Cre;PTEN^{fl/fl}Trp53^{fl/fl} mice. (A-B) Pb-Cre;PTEN^{fl/fl}Trp53^{fl/fl} mice were treated with trametinib (3 mg/kg, *po*, every day) alone and in combination with copanlisib (14 mg/kg, *iv*, every alternate day). Tumor volumes were non-invasively monitored by MRI and % response rate at days 14 (R_{14}) and 28 (R_{28}) were determined, as described in Methods. The % change in solid tumor volume are represented by waterfall plot trametinib (A) and copanlisib + trametinib (B) treated groups. n=5-6 mice per group (experimental male mice with the correct genotype were obtained following screening of 34 littermates derived from 5 breeding pairs and randomized until the indicated number of mice achieved in each group). Significances/p-values were calculated by Chi-square test and indicated as follows, * $p < 0.05$, relative to untreated.